Ankylosing Spondylitis

The FDA has approved Abrilada, a biosimilar to Humira, making it the fifth biosimilar to the reference drug and 25th biosimilar overall to gain approval in the United States, according to an agency press release.

The majority of physical therapists can accurately distinguish between inflammatory and noninflammatory arthritis and understand the importance of correct and prompt referrals to a rheumatologist for suspected inflammatory conditions, according to survey results published in Arthritis Care & Research.

The prevalence of ankylosing spondylitis more than doubled, from 0.04% to 0.09%, from 2006 to 2016, according to data published in BMC Rheumatology.

Continuous use of NSAIDs for the treatment of ankylosing spondylitis is associated with a 12% increased risk for incident hypertension, compared to non-continuous or no NSAID use, according to data published in Arthritis Care & Research.

IBI303, a biosimilar to adalimumab developed by Chinese biopharmaceutical company Innovent Biologics, is comparable in safety and efficacy to the originator drug among patients with ankylosing spondylitis, according to data published in The Lancet Rheumatology.

Newly diagnosed patients with ankylosing spondylitis in Taiwan demonstrate increased risks for multiple immune-mediated inflammatory diseases, including acute anterior uveitis, psoriasis, thromboangiitis obliterans, Behcet’s disease and sarcoidosis, according to findings published in Arthritis Research & Therapy.

EFORT Open Reviews is the new open access journal from EFORT and Bone & Joint Publishing. All articles are free to read online with no subscription required.

The FDA has extended approval for ixekizumab injection 80 mg/mL to treat adults with ankylosing spondylitis – or radiographic axial spondyloarthritis - according to an Eli Lilly press release.

Adults with active ankylosing spondylitis despite treatment with a first TNF-inhibitor, as well as those with stable disease receiving an originator TNF inhibitor, should not be switched to a biosimilar, according to updated recommendations from the American College of Rheumatology published in Arthritis Care & Research.

HILTON HEAD, S.C. — In a duet session focused on spondyloarthritis, Grace Wright, MD, PhD, and Reeti Joshi, MD, detailed the differences between axial and peripheral disease and identified the various features of both in an effort to aid early diagnosis.